On Invalid Date, Cerevel Therapeutics Holdings (NASDAQ: CERE) reported Q3 2023 earnings per share (EPS) of -$0.61, up 7.58% year over year. Total Cerevel Therapeutics Holdings earnings for the quarter were -$96.36 million. In the same quarter last year, Cerevel Therapeutics Holdings's earnings per share (EPS) was -$0.66.
As of Q4 2023, Cerevel Therapeutics Holdings's earnings has grown year over year. Cerevel Therapeutics Holdings's earnings in the past year totalled -$392.99 million.
What was CERE's revenue last quarter?
On Invalid Date, Cerevel Therapeutics Holdings (NASDAQ: CERE) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Cerevel Therapeutics Holdings's revenue was $0.00.
What was CERE's revenue growth in the past year?
As of Q4 2023, Cerevel Therapeutics Holdings's revenue has grown null year over year. Cerevel Therapeutics Holdings's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.